Clinical trials: Acute Vestibular Syndrome
Vertigo, Peripheral
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate) to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of treatment; Evaluation of impact on quality of life in…
- Trial name
- NCT02112578
- Testing
- Meclizine, Dimenhydrinate
- Where
- 7 sites in Brazil
- Volunteers
- 292 people
- Sponsor
- Apsen Farmaceutica S.A.
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Vestibular Vertigo
AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery
Treatment of vertigo after removal of a tumor of the balance and hearing nerve after neurosurgery, which damages or cuts the vestibular nerve (balance).
- Trial name
- TRAVERS (NCT03908567)
- Testing
- Intranasal Drug, Oral Tablet
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Auris Medical AG